Relief measured in months, not days
Our lead product candidate, NGX–4010, is being investigated for its potential to relieve pain by delivering a medication directly to the site of pain. Clinical studies have shown that a single NGX-4010 application to the painful area may provide three months of relief from neuropathic pain, with minimum side effects or drug-drug interactions.

 Learn more about ngx-4010 
 What is Neuropathic Pain? 






Neurogesx News
May 07, 2008
NeurogesX to Report First Quarter 2008 Financial Results
Apr 24, 2008
NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
Mar 26, 2008
NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results

More...

  • About NeurogesX
    • Company History
    • Management Team
    • Board of Directors
    • Advisory Board
  • Product Development
    • About Our Portfolio
    • NGX-4010
    • Clinical Trials
    • Science of TRPV1 Agonism
    • Bibliography
    • Scientific Publications
  • Pain Information
    • What is Pain?
    • For Healthcare Professionals:
    • Types of Neuropathic Pain
    • TRPV1 Agonism
    • Clinical Studies
    • For Patients
    • What is Neuropathic Pain?
    • Resources
    • Join a Clinical Trial
    • FAQs
  • Investor Relations
    • Press Releases
    • Events & Presentations
    • Investor FAQs
    • Contact Us
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
  • Financial Information
    • SEC Filings
  • Stock Information
    • Historic Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Shareholder Tools
    • Shareholder Briefcase
    • Email Alerts
    • Download Library
    • RSS Feeds
  • Careers
    • Career Opportunities
© NeurogesX 2008 | Terms & Conditions
Contact Us | Site Map  Search